Herpes Zoster Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, China, Canada, UK, France, India, Japan, Brazil, Mexico - Size and Forecast 2024-2028

Herpes Zoster Therapeutics Market Size 2024-2028

The herpes zoster therapeutics market size is forecast to increase by USD 5.07 billion at a CAGR of 13.7% between 2023 and 2028.

• The market is experiencing significant growth due to the increasing incidence of shingles, or herpes zoster, and the emergence of innovative vaccines for disease management. However, the market is faced with challenges, including a weak pipeline for new treatments. The demand for antihistamines and other medications to alleviate symptoms is on the rise, as diagnostic centers continue to identify and treat an increasing number of shingles cases. Molecular diagnostics and data analysis are essential tools in the development of new treatment guidelines and vaccine efficacy studies.
• The market's growth is driven by the aging population, as individuals over 50 are at higher risk for developing shingles. Additionally, the availability of effective vaccines, such as the shingles vaccine, is a major factor in the market's expansion. Despite these positives, the market faces challenges, including the high cost of treatment and the limited number of new drugs in development. The market is expected to continue growing, driven by the increasing incidence of shingles and the development of new treatments.

What will be the Herpes Zoster Therapeutics Market Size During the Forecast Period?

Request Free Sample

• The market represents a significant area of interest within the healthcare industry, given the increasing incidence and complications associated with this viral infection. Herpes zoster, also known as shingles, is a painful condition caused by the reactivation of the varicella-zoster virus (VZV). This condition primarily affects the elderly population, and its prevalence is on the rise due to aging demographics and weakened immune systems. Healthcare providers play a crucial role in ensuring the quality of care for herpes zoster patients. Effective diagnosis, timely treatment, and patient education are essential components of managing herpes zoster and its complications, such as post-herpetic neuralgia (PHN).
• Moreover, antiviral therapy is the primary treatment approach for herpes zoster, with cost-effectiveness and health insurance coverage being critical factors in its widespread adoption. The healthcare industry invests heavily in research and development to improve the efficacy of antiviral therapies and develop vaccines for herpes zoster prevention. Immunology and virology research institutes contribute significantly to the understanding of the immune system's role in herpes zoster and the potential for immunosuppression as a risk factor. The herpes zoster market faces challenges in addressing the complications and long-term effects of the condition, such as neurological complications and pain management.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• Product
  • Vaccination
  • Drug therapy
• Geography
  • North America
    • Canada
    • Mexico
    • US
  • Europe
    • Germany
    • UK
    • France
  • Asia
    • China
    • India
    • Japan
  • Rest of World (ROW)

By Product Insights

• The vaccination segment is estimated to witness significant growth during the forecast period.

Vaccines play a crucial role in disease prevention by providing active immunization through the introduction of dead or live microbial antigens. These antigens stimulate the production of antibodies in the body, which remain and offer protection against future infections. Shingles, also known as Herpes Zoster (HZ), is a viral infection caused by the Varicella-zoster virus, which can reactivate in people who have previously had chickenpox. The Centers for Disease Control and Prevention (CDC) recommends the use of Shingrix, a non-live varicella-zoster vaccine, for individuals aged 50 and above to prevent shingles. Shingrix is approximately 90% effective in preventing shingles and postherpetic neuralgia (PHN) in this age group.

Get a glance at the market report of share of various segments Request Free Sample

The vaccination segment was valued at USD 1.97 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

• North America is estimated to contribute 63% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

The market in North America is predominantly driven by the demand for medications and vaccines used to treat and prevent shingles. The region's advanced healthcare infrastructure and rising cases of herpes zoster contribute significantly to the market's growth. The elderly population, particularly those aged 50 and above, are more susceptible to developing shingles due to weakened immune systems. Complications from shingles, such as postherpetic neuralgia (PHN), which causes severe pain in the affected areas, further fuel market expansion. Anticonvulsants are commonly used to manage the pain associated with shingles and PHN. While vaccination is an effective preventive measure against shingles, hospitalizations for its treatment remain frequent due to the disease's chronic nature. The market's growth is expected to continue as research and development efforts focus on creating more effective treatments and vaccines.

Market Dynamics

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise in adoption of Herpes Zoster Therapeutics Market?

Increased incidence of herpes zoster is the key driver of the market.

• Herpes zoster, also known as shingles, is caused by the reactivation of the varicella-zoster virus, which is the same virus that causes chickenpox. After a person recovers from chickenpox, the virus remains dormant in the nervous system. Factors such as aging, stress, and weakened immune systems can reactivate the virus, leading to herpes zoster. The incidence rate of herpes zoster has seen a significant increase in recent decades, with over four-fold growth. Exposure to ultraviolet radiation and other environmental factors may contribute to the weakening of the immune system, making individuals more susceptible to herpes zoster. Antiviral drugs, such as acyclovir and valacyclovir, are commonly used to treat herpes zoster.
• Moreover, these medications help to reduce the severity and duration of the rash and associated pain. In addition, vaccines, including the varicella vaccine and herpes zoster vaccine, have been developed to prevent the initial infection and reactivation of the virus, respectively. These preventative measures are crucial in reducing the incidence and impact of herpes zoster. It is essential to maintain a healthy immune system to minimize the risk of developing herpes zoster. Practicing stress management techniques, getting adequate sleep, and eating a balanced diet can all help to strengthen the immune system. Furthermore, staying informed about the latest research and developments in herpes zoster therapeutics can help individuals make informed decisions about their healthcare.

What are the market trends shaping the Herpes Zoster Therapeutics Market?

Emerging innovative vaccines for disease management is the upcoming trend in the market.

• Herpes Zoster, also known as shingles, is a disease caused by the varicella-zoster virus. Until the advent of vaccines, treatment for this condition relied solely on drug therapies. However, pharmaceutical companies are making significant strides in the development of novel therapies for managing herpes zoster. These new treatments aim to prevent and treat the disease more effectively, particularly in immunocompromised patients. For example, Merck's V 212 is currently undergoing Phase III clinical trials for the treatment of herpes zoster. Preliminary results suggest that this molecule can reduce the occurrence of shingles by 64% in immunocompromised individuals. Once completed, these trials will pave the way for the eventual launch of this treatment in the US and other regions.
• In addition, laboratory testing plays a crucial role in the diagnosis and management of herpes zoster, with serological testing being a common method used to detect the presence of the virus. Clinics specializing in infectious diseases offer comprehensive care for patients diagnosed with herpes zoster, ensuring proper disease management and follow-up care.

What challenges does Herpes Zoster Therapeutics Market face during the growth?

Weak pipeline for herpes zoster is a key challenge affecting the market growth.

• The herpes zoster pipeline features a limited number of agents in development, despite the rising incidence of the infection globally. Few companies are investing in creating new therapies for this indication. The acceptance of herpes zoster vaccines has been inconsistent worldwide. Fear of the infection peaking at an earlier age and the absence of mandatory universal childhood varicella vaccination programs in many countries contribute to this trend. Consequently, while The market holds significant growth potential, the achievable market size for vaccines may remain relatively small.
• Furthermore, the acceptance of vaccines for herpes zoster has been inconsistent due to concerns about the age at which the infection may occur and the absence of mandatory childhood varicella vaccination programs in several countries. These factors impact the market's growth potential, making it essential for companies to focus on addressing these challenges to tap into the market's opportunities. (Word count: 98)

Exclusive Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• Abbott Laboratories
• Bausch Health Companies Inc.
• Cipla Inc.
• East India Pharmaceutical Works Ltd.
• East West Pharma India Pvt. Ltd.
• Eli Lilly and Co.
• Emcure Pharmaceuticals Ltd.
• FDC Ltd.
• GeneOne Life Science Inc.
• GlaxoSmithKline Plc
• Ikon Remedies Pvt. Ltd.
• Leeford Healthcare Ltd.
• Maruho Co. Ltd.
• Merck and Co. Inc.
• Novartis AG
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Zydus Lifesciences Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

Herpes Zoster, also known as shingles, is a viral disease caused by the reactivation of the Varicella-Zoster Virus (VZV), which also causes chickenpox. The disease is characterized by painful blisters that develop on one side of the body, often accompanied by symptoms such as fever, headache, and fatigue. Immunocompromised patients and the elderly are more susceptible to developing herpes zoster. Effective disease management includes early diagnosis through serological testing and laboratory analysis. Diagnostic centers and hospitals play a crucial role in providing accurate diagnoses. Prevention measures include vaccines, such as the Herpes Zoster vaccine, for those at high risk.

Moreover, for those diagnosed with herpes zoster, treatment options include antiviral drugs like acyclovir and valacyclovir, anticonvulsants, antihistamines, and narcotic medications for pain management. Capsaicin cream is also used to alleviate pain associated with post-herpetic neuralgia. Academic institutes and research centers are actively involved in drug development for herpes zoster, exploring new treatments and vaccines to improve patient outcomes. Chronic diseases like herpes zoster require ongoing management to minimize complications and improve quality of life. Symptomatic relief and prevention through vaccination are essential components of herpes zoster therapeutics.

Request Free Sample

What are the Key Data Covered in this Market Research and Growth Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting between 2024 and 2028
• Precise estimation of the size of the market and its contribution of the market in focus to the parent market
• Accurate predictions about upcoming market growth and trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch